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Abstract
The tumor suppressor gene BRCA1 maintains genomic
integrity by protecting cells from the deleterious effects of
DNA double-strand breaks (DSBs). Through its interactions
with the checkpoint kinase 2 (Chk2) kinase and Rad51, BRCA1
promotes homologous recombination, which is typically an
error-free repair process. In addition, accumulating evidence
implicates BRCA1 in the regulation of nonhomologous end-
joining (NHEJ), which may involve precise religation of the
DSB ends if they are compatible (i.e., error-free repair) or
sequence alteration upon rejoining (i.e., error-prone or
mutagenic repair). However, the precise role of BRCA1 in
regulating these different subtypes of NHEJ is not clear. We
provide here the genetic and biochemical evidence to show
that BRCA1 promotes error-free rejoining of DSBs in human
breast carcinoma cells while suppressing microhomology-
mediated error-prone end-joining and restricting sequence
deletion at the break junction during repair. The repair
spectrum in BRCA1-deficient cells was characterized by an
increase in the formation of >2 kb deletions and in the usage
of long microhomologies distal to the break site, compared
with wild-type (WT) cells. This error-prone repair phenotype
could also be revealed by disruption of the Chk2 phosphor-
ylation site of BRCA1, or by expression of a dominant-negative
kinase-dead Chk2 mutant in cells with WT BRCA1. We suggest
that the differential control of NHEJ subprocesses by BRCA1,
in concert with Chk2, reduces the mutagenic potential of
NHEJ, thereby contributing to the prevention of familial breast
cancers. (Cancer Res 2006; 66(3): 1401-8)
Introduction
Chromosomal double-strand breaks (DSBs), which may arise
during physiologic processes, such as replication or V(D)J
recombination, or after cellular exposure to ionizing radiation
and chemotherapy, are the most dangerous form of DNA lesions
(1, 2). DSBs, which can be lethal if unrepaired or mutagenic if
misrepaired, can be removed from the genome by two general
types of genetically largely independent repair mechanisms—
homologous recombination (HR) or nonhomologous end-joining
(NHEJ). HR is typically error-free and requires extensive homology
on a sister chromatid or a homologous chromosome, which may
serve as repair templates to faithfully restore the original DNA
sequence (3). HR is most active in the late S and G2 phases of cell
cycle. In contrast, NHEJ, which is traditionally considered error-
prone, reseals DSBs efficiently throughout all cell cycle phases with
very limited or no homology requirements (4). It has been shown
recently that NHEJ can precisely religate DNA ends without
sequence change if the ends are cohesive and complementary or
blunt [e.g., the signal ends in V(D)J and restriction endonuclease
generated compatible ends; refs. 5, 6]. Alternatively, if error-free
end-joining is not an option (e.g., ionizing radiation–induced DSBs
or restriction endonuclease–induced noncompatible ends), end-
joining is error-prone. This error-prone type of rejoining typically
involves end modification (which can be limited with loss or
insertion of a few nucleotides) or extensive (with deletions up to
hundreds of nucleotides). Given that any deletion arising from the
break site may destroy coding or regulatory sequences, or may
lead to chromosomal aberrations and thereby increase genomic
instability, NHEJ processes must be closely regulated to limit the
resulting mutagenic potential. However, little is known about the
genetic factors that control the extent of sequence alteration
during error-prone repair or that prevent error-prone repair
mechanisms in scenarios where precise end-joining is a potentially
available repair pathway.
Germ line mutations in BRCA1 predispose to breast cancers and
other tumors. BRCA1 has been implicated in a variety of cellular
processes, including DNA repair, replication, cell-cycle control,
apoptosis, transcription, and chromatin remodeling (7, 8). Dys-
function of many or all of these BRCA1 properties may be invoked
in cancer development. Through its interaction with BRCA2/Rad51,
BRCA1 promotes HR, thereby ensuring error-free repair of DSBs
(9–11). It was recently reported that increased breast cancer risk
was highly associated with single nucleotide polymorphisms in
NHEJ genes (12). Interestingly, significantly increased numbers of
high-risk NHEJ genotypes were seen only in women with at least
one variant BRCA1 allele (13). We and others have shown evidence
that BRCA1 plays an active role in regulation of NHEJ. However,
these studies have generated conflicting observations on the role of
BRCA1 in NHEJ, including a promotion of NHEJ, suppressive
effects, or no effect (9, 11, 13–19). These results may at least in part
be a reflection of different roles of BRCA1 in various subtypes of
NHEJ existing in eukaryotic cells (9, 20–22). An increasing body of
evidence suggests that in mammalian cells, DNA-PKcs/Ku–
dependent NHEJ is the main mechanism by which ends are
rejoined precisely or with minimum sequence modification at the
junction. Recently, however, several lines of genetic and biochem-
ical evidence have suggested an alternative NHEJ subpathway that
is independent of Ku80 but strongly dependent on Mre11 and
Rad50 (5, 20, 23–26), which play a central role in sensing and signal
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transduction of DSBs (5, 20, 23–26). This Mre11-dependent
alternative process rejoins chromosomal DNA ends by annealing
the resected 3Voverhanging strands with imperfect microhomology.
In contrast to DNA-PKcs/Ku–dependent NHEJ, the Mre11-mediat-
ed repair pathway is always highly mutagenic with reported
nonrandom deletions of up to 300 bp (5, 20), which results from
searching for microhomology sequences flanking the DSB ends.
Although BRCA1 has not been reported to directly interact with
proteins in the DNA-PKcs/Ku pathway, it physically interacts with
the Mre11/NBS1/Rad50 complex (27). Several recent studies have
linked BRCA1 to Mre11 function. For example, BRCA1 suppresses
the DSB-induced Mre11 response and decreases the efficiency of
random chromosomal integration of exogenous DNA, which is at
least in part mediated by the Mre11 complex (9). Therefore, we
hypothesize that, besides controlling error-free HR, BRCA1 also
maintains genome integrity by promoting precise NHEJ and by
preventing highly mutagenic error-prone microhomology-mediated
end-joining (MMEJ).
Phosphorylation of BRCA1 is an important means by which its
cellular functions are regulated. During the DNA damage response,
BRCA1 is phosphorylated by several protein kinases, such as ATM,
ATR, Chk2, and MDC1 (28–31). The checkpoint kinase 2 (Chk2) is
emerging as a key mediator in the network of genome-surveillance
pathways that coordinate cell cycle progression with DNA repair
and cell survival. In response to DNA damage, Chk2 is activated
and propagates the checkpoint signal along several pathways to
cause cell cycle arrest in the intra-S, and G2-M phases (32). It has
been suggested that Chk2 functions upstream of BRCA1 in the
same pathway involved in maintaining genome integrity and
preventing cancer development (9, 33). Data from our laboratories
have shown that Chk2 phosphorylation at the S988 site of BRCA1,
but not ATM-mediated phosphorylation, is important for the
function of BRCA1 in promoting error-free HR and inhibiting
Mre11-mediated random chromosomal integration (9). However,
Chk2 function has not yet been directly linked to NHEJ-mediated
DSB repair. We have further proposed that phosphorylation of
BRCA1 at S988 by Chk2 controls the function of BRCA1 in
orchestrating multiple submechanisms of NHEJ (9).
In the current study, we seek to define the role of BRCA1 and its
Chk2 phosphorylation site in various NHEJ subpathways at the
DNA sequence level using both naked and chromatinized NHEJ
substrates. We find that BRCA1 promotes error-free NHEJ while
preventing error-prone MMEJ and restricting sequence deletion
upon error-prone repair. Both the Chk2 kinase activity and its
phosphorylation site are critical for BRCA1 to differentially regulate
various sub-NHEJ mechanisms and to prevent large deletion
formation by rejoining along long distal microhomologies. Thus, we
suggest that BRCA1, in concert with Chk2, actively regulates NHEJ
processes to reduce their mutagenic potential.
Materials and Methods
Cell lines, transfections, infections, and Western blots. HCC1937
human breast carcinoma cells were established and maintained as
described (9). Briefly, parental HCC1937 cells were stably transfected with
an expression plasmid for wild-type (WT) BRCA1, the Chk2 phosphoryla-
tion mutant, or an empty vector control (pcDNA3-BRCA1, pcDNA3-BRCA1-
S988A, or pcDNA3, respectively). All transfections were done using
LipofectAMINE (Invitrogen, Carlsbad, CA) and BRCA1-expressing clones
were selected with G418 (300 Ag/mL, Mediatech, Inc., Herndon, VA). Clones
were screened for comparable expression level of WT or mutant BRCA1
protein by immunoprecipitation and immunoblotting (Ab-3 and Ab-1,
respectively; Oncogene, San Diego, CA). For transient expression of WT
Chk2 or kinase-dead (KD) Chk2 mutant, HCC1937 cells were infected with
recombinant adenovirus with cytomegalovirus promoter–driven Chk2-WT
or Chk2-KD at 10 plaque-forming units per cell (31, 34). Total cell lysates
were prepared 24 hours after infection to confirm comparable protein
expression levels of Chk2-WT and Chk2-KD with Western blot probed with
mouse anti-Chk2 antibody (Ab-12 Santa Cruz Biotechnology, Inc., Santa
Cruz, CA).
Plasmid construction. The plasmid pGL3-MCS as a substrate for end-
joining–mediated recircularization was derived from pGL3-Control (Prom-
ega, Madison, WI). To introduce additional unique restriction cleavage sites
between the promoter and the luciferase gene, part of the multiple cloning
site of pcDNA3.1/Zeo (Invitrogen) was amplified by PCR. This PCR frag-
ment (106 bp) was inserted into the unique HindIII site of pGL3-Control.
The integrity of the fragment was verified by DNA sequencing. Blunt-ended
DSBs were created by EcoRV cleavage and cohesive ends were created by
digest with ApaI or SalI (pGL3-MCS) or HindIII (pGL3-Control) enzymes.
The plasmid pEPI-HDV6 as the substrate for the transposon excision
assay was derived from pDVH6. pDVH6 contains a Tn5 minitransposon that
can be excised by Tn5 transposase, thereby creating a blunt-ended DSB. The
polyoma sequence in the plasmid enables stable episomal replication in
murine cells (6). The plasmid pEPI-GFP, which carries a human scaffold/
matrix-attached region and allows sustained episomal replication without
chromosomal integration in human cells, was generously provided by
Dr. H.J. Lipps (35). The 2.6 kb PvuII fragment of pDVH6 containing all the
elements required for the Tn5 transposase excision assay was subcloned
into the EcoRV site of plasmid pEPI-GFP (35). This generated pEPI-HDV6,
which allows for assessment of Tn5 transposon excision and end-rejoining
in a chromatinized context in human cells. To confirm the episomal
replication of pEPI-HDV6, extrachromosomal plasmids were harvested at
days 15, 22, and 35 after transfection of HCC1937 cells using the EZNA
plasmid miniprep kit (Omega Bio-tek, Doraville, GA) and subjected to
restriction digestion with either DpnI or MboI. After replication in human
cells, the plasmids are sensitive to MboI but resistant to DpnI digestion
(NEB, Ipswich, MA). The mitotic stability of the episomal plasmid was
determined by quantifying the copy number of the episomal plasmid
using Southern blot analysis of extrachromosomal plasmid extracted up to
35 days after transfection.
Assay of NHEJ by circularization of linear plasmid substrate. pGL3-
MCS was cleaved between the promoter and luciferase reporter gene.
Linearized DNA was gel purified for human cell transfection. Cells were
cotransfected with a pRL-SV40 internal control (renilla luciferase, Promega)
and either cleaved substrate or a circular positive control using Lipofect-
AMINE. All transfections were done in parallel. Cell extracts were prepared
24 hours later according to the instructions of the manufacturer and
assayed in a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA) using
the Dual-Luciferase Reporter assay System (Promega). The relative DSB
rejoining activity was obtained by comparison of firefly luciferase activity
detected in cells transfected with linearized substrate relative to cells
transfected with circular plasmid corrected for transfection efficiency and
expression levels.
For physical analysis of repair products, plasmid DNA was extracted
24 hours after transfection as described (36). The DNA was transformed into
electrocompetent bacteria (DH10B, Invitrogen), followed by plating onto
fresh Luria-Bertani agar plates containing 50 Ag/mL ampicillin. Small-scale
DNA preparations were made from bacterial colonies (Qiagen, Hilden,
Germany) and subjected to restriction fragment analysis, PCR amplification,
and sequencing (see text and figure legends for details).
Assay of NHEJ by Tn5 transposon excision. Seven days after
transfection of pEPI-HDV6 into HCC1937 cells, cells were infected with
recombinant adenovirus expressing either Chk2-WT or Chk2-KD. On the
following day, cells were transfected with the Tn5 transposase expression
vector pDVG-148. Extrachromosomal plasmids were harvested at day 10
for analysis of NHEJ. To assess the relative level of overall end-joining,
recovered plasmids were subjected to DpnI digestion and PCR amplification
using primers flanking the transposon region (5V-GGCTAACTAGAGAACC-
CACTGCTTA-3Vand 5V-GACCGGTGTCAGATTATGCAGCAA-3V). PCR products
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were separated on 8% polyacrylamide gel in Tris-borate EDTA buffer, silver
stained using Silver Stain Plus from Bio-Rad (Hercules, CA), and analyzed
using the Quantity One Analysis Software (Bio-Rad). To determine the
nature of NHEJ events, the recovered extrachromosomal DNA were digested
with BamHI and NheI before PCR amplification to remove plasmids that
did not undergo transposon excision. PCR products digested with EcoRV
endonuclease, which cleaves precise rejoining products, or BstXI, which
cleaves the imprecise NHEJ products using a designed 6 bp microhomology
sequence flanking the DSB (Fig. 3), were subjected to gel separation and
quantification.
Results
BRCA1 promotes overall DSB end rejoining. To study the
role of BRCA1 on NHEJ at the DNA sequence level in living human
cells, we started out by using a commonly used reporter reactivation
assay (15, 17, 37). The plasmid substrate pGL3-MCS was cleaved by
the EcoRV restriction endonuclease in vitro between the promoter
and the luciferase reporter gene, thereby preventing expression of
the reporter in vivo (Fig. 1A). The linearized plasmid was introduced
together with an internal control plasmid into a previously well-
characterized isogenic pair of HCC1937 breast carcinoma cells with
or without stable expression of WT BRCA1 ( for the BRCA1 S988
mutant, see below; Fig. 1B ; ref. 9). Intracellular recircularization of
linearized DNA was detected by measuring luciferase activities
following 24 hours of incubation. The rejoining levels in BRCA1-
deficient cells were significantly reduced compared with cells with
restored WT BRCA1 (i.e., 13.4% versus 24.1% rejoining of linear
substrate relative to circular control transfected in parallel,
respectively; Fig. 1C). The effect of BRCA1 on NHEJ was not depend-
ent on the type of double-stranded ends present: The difference in
the rejoining of blunt ends (EcoRV) between cells with and without
WT BRCA1 (Fig. 1C) was comparable with the difference in the
repair of cohesive ends, which was 12.8% versus 27.6% (P < 0.01; data
not shown). Thus, WT BRCA1 is required for proficient rejoining of
linearized extrachromosomal plasmid substrates.
It has been speculated that the mechanisms of recircularization
of ‘‘naked’’ extrachromosomal linearized DNA may be different
from the rejoining of chromosomal DSBs, which are packed in
highly organized chromatin. For example, the status of the DNA-
PKcs or XRCC4 genes, which are essential for V(D)J recombination
and cellular resistance to X-rays, only have a mild effect on
recircularization of linearized substrate DNA (22, 37–39).
Therefore, to verify the results obtained with naked, non-
replicating DNA substrates, we used an assay based on the
rejoining of blunt-ended DSBs generated by expression of Tn5
transposase in a chromatinized episomal replicating plasmid
substrate pEPI-DVH6 in human cells (Fig. 2A). This transposon
excision assay has been developed previously and has been success-
fully used to show the roles of DNA-PK, XRCC4, and MDC1 in the
control of NHEJ in murine cells (6, 40). Briefly, transient expression
of Tn5 transposase in HCC1937 cells carrying the episomally
replicating pEPI-DVH6 substrate generates blunt-ended DSBs at
the defined Tn5 transposon recognition sites within the substrate
(Fig. 2A). Transposon excision and end-joining can be determined
by PCR amplification of the region containing the transposon.
Without transposon excision, PCR amplification of pEPI-DVH6
gives rise to a product of 487 bp, whereas after transposon excision
and end-rejoining the PCR fragments are shorter (146 bp; Fig. 2B).
Consistent with the previous recircularization assay (Fig. 1C), the
loss of BRCA1 resulted in a 3.2-fold reduction in the relative
efficiency of DSB rejoining, e.g., 2.4 F 0.16% in vector-transfected
BRCA1-null HCC1937 cells compared with 7.7% F 0.01% in cells
with WT BRCA1 (Fig. 2C). We also determined that BRCA1 status
had no significant effect on either the copy number of the
episomally replicating pEPI-HDV6 plasmid, measured using both
Southern blot analysis and Escherichia coli transformation
efficiency, or the transfection efficiency, determined by an YFP
expression vector (data not shown).
To determine if the phosphorylation of BRCA1 regulates its
function in NHEJ, we used a phosphorylation mutant of BRCA1,
which contained a serine 988 to alanine substitution (S988A),
thereby abrogating phosphorylation of BRCA1 by Chk2 (9, 41). We
examined the relative overall rejoining efficiencies in HCC1937 cells
stably expressing either WT BRCA1 or the S988A mutant (Fig. 1B).
As shown in Fig. 1C and 2C , the levels of overall NHEJ in S988A-
expressing cells were increased by almost 2-fold compared with
vector-alone transfected BRCA1-deficient cells, although for the
transposon assay the NHEJ level in S988A-expressing cells did not
reach the same rejoining proficiency produced by the presence of
WT protein, as observed with the luciferase assay (Fig. 1C). It is
possible that this difference is due to a different degree of usage of
the various NHEJ subpathways in the repair of DSBs in naked DNA
versus chromatinized DNA (6).
Chk2 kinase activity has not been directly linked to NHEJ. We
reasoned that if the effect of the S988A mutant on overall NHEJ truly
resulted from its resistance to Chk2 kinase–mediated phosphory-
lation, disruption of the kinase activity of Chk2 would result in
decreased NHEJ in BRCA1-proficient cells but would not affect
overall NHEJ in cells deficient for BRCA1 or expressing the S988A
mutant. Therefore, we infected HCC1937 cells with different BRCA1
status with recombinant adenovirus expressing either Chk2-WT or
Chk2-KD, which inhibits the kinase activity of endogenous WT Chk2
Figure 1. Intramolecular NHEJ measured by an episomal plasmid assay. A, the
luciferase (LUC )-based reporter plasmid, pGL3-MCS, offers a set of unique
restriction enzyme cleavage sites, including EcoRV, between the promoter and
the LUC gene. Pvu I sites are used for deletion size mapping (see Fig. 6A for
further details). B, the protein expression levels of WT BRCA1 and the S988A
mutant in HCC1937 cells. C, the rejoining of EcoRV-cleaved plasmid ends was
measured by the LUC activity detected in cells transfected with linear plasmid
substrate relative to circular plasmid control.
Role of BRCA1 in NHEJ
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in a dominant-negative fashion (31, 34). Comparable expressing
levels of Chk2-WT or Chk2-KD were achieved (Fig. 2D). Consistent
with the observed rejoining proficiency of S988A-expressing cells, we
found that expression of Chk2-KD had no additional effect on the
overall NHEJ efficiency regardless of the BRCA1 status (Fig. 1C and
2C). We conclude that despite the dependence of BRCA1 promotion
of HR on Chk2-mediated phosphorylation, Chk2 plays a less
important role in the promotion of BRCA1-dependent overall NHEJ
proficiency, which represents the combined DSB rejoining efficien-
cies of various NHEJ subpathways.
Promotion of error-free NHEJ by BRCA1 depends on Chk2
phosphorylation at the S988 site. Different subpathways of NHEJ
may dictate the repair of the plasmid substrate by either error-free
direct ligation or by error-prone MMEJ. To determine whether the
fidelity of end-joining is controlled by Chk2 phosphorylation of
BRCA1, we used the pEPI-HDV6 substrate. The sequences flanking
the Tn5 transposon have been designed in such a way that precise
rejoining of the DSB ends would generate an EcoRV restriction site
(Fig. 3A), whereas imprecise MMEJ using a 6-bp microhomology
that directly flanks the transposon would generate a novel BstXI
restriction site (6). This sequence arrangement allowed us to detect
the relative efficiencies of these different NHEJ repair events by
digestion of the PCR products with either EcoRV or BstXI (Fig. 3B).
The relative efficiencies of precise rejoining were assessed in
HCC1937 cells with different BRCA1 status (Fig. 3C ; ref. 9). Loss of
Figure 3. Influence of BRCA1 and its phosphorylation site on fidelity of NHEJ.
A, schematic representation of the transposon excision reaction to assess
error-free versus error-prone NHEJ. B, the precise repair of the DSB ends
without alteration of sequence creates a novel EcoRV restriction site. Imprecise
end-joining using a stretch of 6 bp microhomology (MMEJ) flanking the DSB
creates a novel BstXI site. Digestion of PCR product with EcoRV (E) or BstXI
(B ) enzymes generates two shorter fragments, respectively. C, the relative
levels of precise rejoining per EcoRV digestion of recovered pEPI-HDV6 were
quantified similarly as described in Fig. 2C . D, the relative levels of imprecise
rejoining determined by sequencing analysis of individual recovered pEPI-HDV6
molecules. Columns, mean of three to seven independent experiments; bars, SE.
Figure 2. Intramolecular NHEJ measured by a chromatinized episomal plasmid
assay (A ). The transposon excision assay plasmid, pEPI-HDV6, contains two
Tn5 ends in inverted orientation (triangles ) and the scaffold/matrix-attached
region (S/MAR ) sequence, which enables sustained episomal replication of the
plasmid in human cells. After transfection of Tn5 transposase expression
plasmid, the Tn5 minitransposon is excised. B, products obtained by PCR
amplification over the Tn5 substrate. In the absence of Tn5 transposase (Tpase)
expression, the intact transposon region amplified by PCR produced a 488 bp
fragment. Upon Tn5 transposase expression, the excision of the transposon and
the rejoining of the flaking ends produced a shorter fragment. C, the quantity
of the PCR fragment was analyzed using the Quantity One Analysis Software
from Bio-Rad. The relative efficiencies of DSB rejoining were calculated
accordingly. Columns, mean of three to seven independent experiments; bars,
SE. Comparisons were made between isogenic HCC1937 cells stably
transfected with WT BRCA1, the Chk2 phosphorylation site mutant (S988A), or
empty control vector, and the additional transient expression of WT or KD Chk2.
*, P values for comparison with WT BRCA1 (Fisher’s exact test). D, the protein
expression levels of Chk2 WT and Chk2 KD in HCC1937 cells with different
BRCA1 status as indicated.
Cancer Research
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BRCA1 WT function or mutation at the Chk2 phosphorylation site
resulted in a 2.5- to 3-fold decrease in the efficiency of precise
religation compared with cells with WT BRCA1 (27 F 0.5% and
31 F 3% versus 78 F 3%, respectively). In addition, by using
sequencing analysis of the break junction, we confirmed an
increased percentage of imprecise rejoining events (i.e., resistant to
EcoRV digestion) in cells expressing the S988A mutant (Fig. 3D),
which mirrors the reduced frequency of precise events measured by
EcoRV digestion (Fig. 3C). To confirm that Chk2 phosphorylation at
the S988 site is critical for the role of BRCA1 in precise rejoining,
we also showed that expression of the dominant-negative Chk2-KD
mutant led to a significant 25% reduction of religation in cells with
WT BRCA1 (P = 0.02), but not in cells deficient for BRCA1 or
expressing the S988A mutant, compared with cells expressing
exogenous WT Chk2 (Fig. 3C and D). Thus, we provide genetic
evidence for a promotion of precise DSB ligation and inhibition of
imprecise end-joining by BRCA1 that is controlled by Chk2-
mediated phosphorylation.
In a second approach, we also used the recircularization assay
with the linearized pGL3-MCS substrate to examine the role of
BRCA1 phosphorylation in the fidelity of rejoining. Twenty-four
hours after transfection of the linearized substrate, plasmids
were extracted from the cells and amplified in bacteria. Precisely
rejoined plasmid retained the EcoRV restriction site as determined
by PCR with primers flanking the DSB and susceptibility to EcoRV
digestion (Fig. 4A). A total of 689 colonies were analyzed.
Interestingly, different from the transposon assay, decreased levels
of error-free NHEJ were only seen in BRCA1-deficient cells (34%),
but not in cells with S988A compared with cells expressing the WT
protein (45-49%, P = 0.04; Fig. 4B). Again, it is possible that the
differential effect of the S988A mutant on end-joining using the
pGL3-MCS substrate versus pEPI-HDV6 is linked to the previously
reported use of different NHEJ mechanisms in the repair of naked
versus chromatinized DSBs (6) but this was not investigated
further (see also Discussion).
BRCA1-mediated suppression of error-prone rejoining and
deletional MMEJ is controlled by Chk2 phosphorylation. Using
the chromatinized pEPI-HDV6 substrate in HCC1937 cells with
different BRCA1 status, we next studied the role of BRCA1 in
deletional imprecise MMEJ. We used the designed 6 bp micro-
homology sequence directly flanking the DSB described above
(Figs. 3A and B). Consistent with the increased levels of imprecise
rejoining in BRCA1-deficient cells (Figs. 3C, D and 4B), we found a
strong 13-fold and 11-fold induction of the relative levels of
deletional MMEJ in cells deficient for WT BRCA1 (5.5 F 1%, P =
0.013) or expressing the S988A mutant (5.1 F 0.8%, P = 0.023)
compared with cells with WT protein (0.5 F 0.2%; Fig. 5A). To
confirm that Chk2-mediated phosphorylation is required for the
apparent inhibition of error-prone MMEJ by WT BRCA1, we
expressed Chk2-KD, which resulted in a 7.3-fold increase of MMEJ
levels only in BRCA1-proficient cells compared with Chk2-WT
expressing control cells (3.5 F 0.4% versus 0.5 F 0.2%, P < 0.01). By
contrast, there was no effect in BRCA1-deficient cells or in cells
expressing the S988A mutant (Fig. 5A). Thus, our results suggest
that Chk2 controls the function of BRCA1 in the prevention of
imprecise end-joining and deletional MMEJ through phosphoryla-
tion at the S988 site.
Mutation of Mre11 in yeast has been reported to shift the
spectrum of nonhomologous repair products toward a decreased
proportion of rejoining mediated by 8 to 10 bp of microhomology
(20). Given the observation that BRCA1 inhibits the function of
Mre11 in vivo (9) and in vitro (42), we therefore sought to
determine whether an opposite shift (a relative increase of longer
stretches of microhomology) could be detected upon loss of BRCA1
function. For this approach, we preferred to use pGL3-MCS over
pEPI-HDV6 because pGL3-MCS offers various stretches of micro-
homology around the cleavage site (see Fig. 5D and below). The
break junction of a sample of 204 error-prone repair products was
sequenced (i.e., products that had lost the EcoRV site). In the
presence of BRCA1, 43% of all repair events were mediated by
flanking microhomologies (Fig. 5B). In contrast, in the absence of
BRCA1 or upon loss of the Chk2 phosphorylation site, the
proportion of rejoining events using any microhomology length
was significantly elevated to 65% to 72% (P V 0.02). The break
junctions of a representative sample of 204 error-prone repair
products were sequenced and analyzed. We showed that the vast
majority of microhomologies in cells with WT BRCA1 were of 1 to 5
bp length, as commonly observed in NHEJ (Fig. 5C ; ref. 4). Some
typically used microhomologies are illustrated in Fig. 5D . In
contrast, in BRCA1-deficient cells or in cells expressing the S988A
mutant, there was a significant shift toward use of a stretch of 8 bp
microhomology that flanked the break site at a distance off50 bp
on either side (i.e., an increase to 43% to 75% in the presence of
S988A versus 7% in cells with WT BRCA1; P V 0.04). The majority of
1 to 5 bp microhomologies used for rejoining were located between
these 8 bp stretches. Taken together, the data indicate that the
Chk2 phosphorylation site controls deletion size and micro-
homology usage during error-prone NHEJ.
BRCA1-mediated restriction of deletion formation is de-
pendent on the Chk2 phosphorylation site. Error-prone NHEJ
often involves limited deletion of no more than a few nucleotides at
the site of rejoining (4), but more extensive loss of sequence can
Figure 4. BRCA1 and its phosphorylation site are required for error-free NHEJ.
A, a representative spectrum of individual repair products recovered from
transfected cells for measuring the precise recircularization of pGL3-MCS
plasmid. Preservation of the cleavage site upon error-free religation of the break
ends generates two bands of 176 and 242 bp from PCR amplification of the
region including the junction (lanes 3, 4, 6, 9 , and 10 ). B, the proportion of
error-free events among all repair events with pGL3-MCS. Columns, mean of
three to seven independent experiments; bars, SE.
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also be observed (20). To study the effect of BRCA1 phosphory-
lation on deletion formation, we subjected the error-prone repair
products to further analysis. Virtually all products were found to
have arisen from deletion events (data not shown). Initial experi-
ments categorized the deletions into three arbitrary classes (i.e.,
V175 bp versus 176 to 2,000 bp versus >2,000 bp; Fig. 6A and B). In
the presence of WT BRCA1, almost 50% of deletions were V175 bp,
whereas only in a few cases (8%) the deletion size exceeded 2,000
bp (Fig. 6C). Conversely, BRCA1-deficient cells showed the opposite
pattern, with a lower percentage of V175 bp deletions and a higher
percentage of large deletions (i.e., 30% and 20%, respectively; P <
0.03). Interestingly, the distribution of deletion sizes in the presence
of the S988A mutant revealed a phenotype that was almost
identical to the spectrum of products seen with BRCA1 deficiency.
Of note, in the S988A-expressing cells, the 12% relative increase
in the proportion of >2,000 bp deletions, which extended into the
promoter and luciferase gene regions, could not be detected as a
reduced level of luciferase activity (Fig. 1C). We estimated that such
a 12% increase would have only led to an f3% drop in luciferase
activity compared with WT cells, which would have been within the
error-margin of the assay ( for WT cells, mean luciferase activity,
24.1%; 95% confidence intervals, F8.5%).
To determine whether cell cycle kinetics might have contributed
to the observed differences, we examined cell cycle distributions by
flow cytometric analysis as described previously (9). The propor-
tion of cells in the G1, S, and G2 phases was similar in control and
BRCA1-expressing cells (data not shown). Thus, the spectrum of
deletion sizes was not due to variations in cell cycle distribution of
the cell lines under study.
Discussion
A growing body of evidence implicates that BRCA1 actively
regulates both principal DSB repair mechanisms, HR and NHEJ. We
have previously shown that abrogation of Chk2-mediated phos-
phorylation of BRCA1 at the S988 site or absence of WT BRCA1
protein affected NHEJ as measured by random chromosomal
integration of a plasmid substrate (9). However, the effect of BRCA1
on integration frequencies could have been the result of multiple
factors. Whether a particular NHEJ subpathway was controlled by
BRCA1 was unknown. In this study, we investigated the effect of
BRCA1 on the proficiency and fidelity of DSB repair through
various NHEJ subpathways and the role of posttranslational
modification of BRCA1 by Chk2 phosphorylation. The evidence
presented here shows that BRCA1 controls two aspects of end-
joining: It promotes error-free NHEJ while inhibiting error-prone
MMEJ and minimizing the size of deletions found in association
with rejoining. Furthermore, the Chk2-mediated phosphorylation
of BRCA1 was critical for the differential roles of BRCA1 in
controlling precise end-joining and mutagenic MMEJ.
A strength of our study was the use of a strictly isogenic cell
system with genetic manipulation on two different protein levels,
BRCA1 and Chk2, as well as the use of two different repair assays,
which yielded largely comparable results. Interestingly, the overall
rejoining levels seen with ‘‘naked’’ DNA (pGL3-MCS; 15-20%)
seemed higher than with chromatinized DNA (pEPI-H6; <10%),
which may represent a differential accessibility of the substrate
DNA for repair enzymes (see also below). We acknowledge that that
imprecise repair of the plasmid ends in pGL3-MCS could have
potentially affected luciferase expression levels. For example, large
deletions may extend toward the viral promoter compromising
transcription or destroy the downstream translational initiation
site. As a result, measuring luciferase expression levels might have
underestimated the true overall rejoining proficiency of the cell.
However, the use of a PCR-based approach in the chromatinized
pEPI-H6 system, which is less influenced although not completely
independent of sequence changes originating from the break
junction (Fig. 2C), corroborated the luciferase expression results.
Figure 5. Function of BRCA1 in prevention of error-prone MMEJ depends on Chk2-mediated phosphorylation. A, the relative levels of deletional MMEJ using a flanking
6 bp microhomology in the transposon excision substrate pEPI-HDV6 in cells with different BRCA1 and Chk2 status were determined as described in Fig. 3.
B, proportion of DSB rejoining along microhomologies of any length among all error-prone repair products, as determined by DNA sequencing of the recircularized
pGL3-MCS. C, proportion of DSB rejoining according to length of microhomologies in the V175 bp deletion class. Central confidence intervals (68%) were calculated
because some of the proportions approached 0% or 100%. D, microhomology usage around the EcoRV cleavage site. Typical 2 to 4 bp microhomologies as well
as the 8 bp stretches are underlined. Indicated is the start codon for the luciferase open reading frame. Columns, mean of three to seven independent experiments;
bars, SE.
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In support of our findings, another study using a different NHEJ
substrate and cell lines observed that the promotion of BRCA1
on precise DSB end-joining was dependent on Chk2 kinase to
phosphorylate BRCA1 at S988 site (44). Our results are also
consistent with previous reports demonstrating a promotion of
end-joining activity by BRCA1 using retroviral or plasmid
substrates (13, 15, 16). In our system as well as in other reports,
DNA-PKcs or XRCC4 deficiency did not significantly reduce the
efficiency of recircularization of cleaved plasmid (data not shown;
refs. 5, 6, 22, 37–39). The recircularization efficiency has been
shown to be relatively less dependent on a DNA-PKcs/
Ku–mediated mechanism but more readily affected by a MMEJ-
based mechanism. Our observation that the effect of BRCA1 on
error-free end-joining was evident only in repairing chromatinized
DNA but not naked DNA implies that (a) the promoting function
of BRCA1 on error-free end-joining seems to be at least partially
associated with the DNA-PKcs/Ku–dependent pathway; and (b)
the presence of an alternative NHEJ pathway such as MMEJ. The
physical and functional interrelationship between BRCA1 and the
components of DNA-PKcs/Ku pathway needs to be defined in
future investigations.
Our results also suggest that the Chk2 phosphorylation site of
BRCA1 controls some but not all of the functions of BRCA1 in
NHEJ. It seems that the complete absence of the BRCA1 protein
causes a more severe overall repair phenotype than the presence
of a protein with the Chk2 phosphorylation site mutated (Fig. 1).
We speculate that this phosphorylation site is required for the
modification of NHEJ fidelity by BRCA1. A possible downstream
mechanism for this effect involves the activity of the Mre11
protein, which interacts with BRCA1 (27, 42, 43). Interestingly,
when we analyzed the repair spectra with regard to micro-
homology usage, we detected a shift in the utilization of regions
of 1 to 5 bp to a more distal region of 8 bp in BRCA1-null and
S988A-expressing cells, compared with cells with WT protein.
This repair phenotype is reminiscent of a Mre11-mediated repair
activity in light of recent observations in yeast, which have
revealed that error-prone NHEJ utilizing flanking 8 to 10 bp
microhomologies was strongly dependent on Mre11 (20). Deletion
formation and usage of distant microhomologies is likely linked
to the biochemical properties of Mre11, including its exonuclease
and annealing activities (20, 45). BRCA1 strongly binds to double-
stranded DNA, thereby inhibiting the nucleolytic activity of the
Mre11 complex (42). Impaired phosphorylation at the S988 site,
which resides in the DNA-binding region of BRCA1, may disrupt
the direct inhibitory effect on Mre11 function, although this
remains to be shown directly (9, 42). The mechanisms by which
the interaction between Chk2, BRCA1, and Mre11 affects the
frequency and fidelity of NHEJ processes await further study.
In conclusion, as a central regulator of the cellular response to
DSBs, BRCA1 may influence DSB processing and repair at an early
stage. The BRCA1 protein becomes rapidly hyperphosphorylated
after induction of DNA damage (45, 46). Chk2-mediated phos-
phorylation of BRCA1 seems critical for the reported active
regulation of both principal repair mechanisms HR and NHEJ (9).
This suggests that BRCA1 functions at a point upstream in the
response pathway where it helps determining whether a break is
channeled toward an error-free homologous or a error-prone
nonhomologous repair process. In addition, BRCA1 may modulate
NHEJ processes to restrict the extent of sequence deletion at the
break site. We suggest that in addition to its promotion of HR, the
detailed control of NHEJ processes by BRCA1, in concert with
Chk2, reduces the mutagenic potential of NHEJ, thereby contrib-
uting to the prevention of familial breast cancers.
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